methylome sequencing
The company raised $60 million last week and will use the funding to develop and validate its DNA methylation-based tests and classifier algorithm.
Liquid Biopsy Startup Adela Launches With $60M Series A Financing Round
The Toronto-based company will use the funding to commercialize its cell-free DNA methylation sequencing technology as an early cancer detection test.
Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
Data Supports Singlera's PanSeer Test as Company Narrows Focus to Colorectal Cancer Detection
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.